# Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

> **NCT02983097** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 34 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma Grade III (FL III°)
- Mantle Cell Lymphoma (MCL), Blastoid Variant
- Burkitt Lymphoma (BL)
- Aggressive Marginal Zone Lymphoma (MZL)

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Dexamethasone
- **DRUG:** Cytarabine
- **DRUG:** Lenalidomide
- **DRUG:** PegFilgrastim
- **PROCEDURE:** peripheral stem cell collection

## Key facts

- **NCT ID:** NCT02983097
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2014-01
- **Final completion:** 2015-04-28
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Phase II: no scientific interests are given anymore
- **Last updated:** 2018-01-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983097, "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02983097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*